Life science news 3 August 2026: argenx pays $2.2 billion for what it calls a first-in-class anti-CD122 antibody, Johnson & Johnson strikes agreements worth up to $3.5 billion with in vivo CAR-T developer Sail Biomedicines, and GSK launches a £1.9 billion savings programme alongside a £400 million UK investment in a busy week for pharma, biotech and healthcare.
argenx announced on 27 July that it has entered into a definitive agreement to acquire Forte Biosciences for $77 per share in cash, representing total equity value of approximately $2.2 billion. The Amsterdam-headquartered immunology company will make a cash tender offer for all outstanding Forte shares, at a premium of about 86 per cent to the target’s volume-weighted average price since it reported positive Phase 1b vitiligo data on 9 July. The deal centres on FB102, which argenx describes as a first-in-class anti-CD122 antibody, with clinical proof of concept in vitiligo and coeliac disease and which the companies describe as a potential pipeline-in-a-product with further scope in alopecia areata and other autoimmune conditions. FB102 targets pathogenic T-cell and natural killer cell activity, a mechanism distinct from the FcRn and complement pathways that underpin argenx’s existing portfolio, led by Vyvgart. Chief Executive Karen Massey said the addition of FB102 aligns with what she called the argenx playbook of compelling biology, strong clinical validation and broad potential to address patient need. The transaction builds on argenx’s earlier strategic investment in Forte, has been approved by both boards, and is expected to close in the third quarter of 2026, subject to the tender of a majority of outstanding shares and expiry of the Hart-Scott-Rodino waiting period.
Johnson & Johnson announced on 29 July a set of strategic agreements with Sail Biomedicines, a Flagship Pioneering company developing in vivo CAR-T therapies for immune-mediated diseases, alongside an exclusive option to acquire the business outright for $2.58 billion. Under the terms, Johnson & Johnson would make total initial payments of $785 million, including a $465 million equity investment through its corporate venture arm, with a further $140 million contingent on development milestones. The collaboration covers Sail’s lead immune-mediated disease programme, the preclinical candidate SAIL-0839, and its broader platform, which Sail describes as combining a circular Endless RNA format, targeted lipid nanoparticles designed to transfect CD4 and CD8 T cells after intravenous administration, and AI-enabled design. In vivo approaches aim to generate engineered T cells inside the patient’s body, removing the individualised manufacturing step that constrains conventional autologous CAR-T. John Reed, Executive Vice President, Innovative Medicine Research and Development at Johnson & Johnson, said Sail’s platform seeks to harness the power of CAR-T therapy in a simpler and more scalable way. Assuming the option is exercised, the company expects dilution to adjusted earnings per share of approximately $0.18 in 2026 and $1.28 in 2027. The transactions are subject to regulatory approvals and other conditions.
Replimune reported on 30 July that the US Food and Drug Administration’s Cellular, Tissue and Gene Therapies Advisory Committee voted 10 to 3 that the efficacy results from its IGNYTE study are evaluable and clinically meaningful. The meeting considered the biologics licence application resubmission for RP1 (vusolimogene oderparepvec) in combination with nivolumab in advanced melanoma patients who have progressed on a prior anti-PD-1 containing regimen. The favourable vote came despite agency reviewers questioning whether the single-arm study allows a reliable determination of response rate and durability, and describing the overall survival analysis as difficult to interpret. Sundeep Agrawal of the FDA’s Oncology Center of Excellence told the committee that the agency’s flexibility does not extend to accepting unreliable efficacy data or waiving the requirement for substantial evidence of effectiveness. Replimune has reported an objective response rate of approximately 34 per cent and a median duration of response of 24.8 months in the anti-PD-1-failed population, and its shares more than doubled in pre-market trading the following morning. The resubmission seeks accelerated approval, with the ongoing Phase 3 IGNYTE-3 trial intended to serve as the confirmatory study. RP1 has received two complete response letters, in July 2025 and April 2026, and the FDA’s target action date under the class 1 resubmission was 2 August 2026. The agency had not announced a decision at the time of publication.
The US Food and Drug Administration announced on 29 July that it has licensed Ezplaz Freeze Dried Plasma, the first freeze-dried plasma product licensed for use in the United States. The biologics licence was granted to Vascular Solutions, a subsidiary of Teleflex. Ezplaz is a lyophilised plasma product derived from a single unit of fresh frozen plasma collected from FDA-licensed blood establishments, and is indicated for transfusion in adults who require plasma when other plasma products are not available, including bleeding patients, those needing massive transfusion and certain patients on warfarin who are bleeding. Unlike conventional plasma, which must be stored frozen and thawed before use, Ezplaz can be stored at room temperature, is stable after exposure to temperature fluctuations and is rapidly reconstituted. It is packaged in a plastic bag rather than a glass bottle, reducing the risk of breakage during handling and transport, and is supplied in Group AB and Group A with low-titre anti-B blood types to mitigate the risk of administration in emergencies before a patient’s blood type is known. Karim Mikhail, Acting Director of the Center for Biologics Evaluation and Research, said the decision addresses an important unmet need, particularly for military personnel and others far from traditional hospital infrastructure.
In further life science news 3 August 2026, the week brought half-year and quarterly results from three of the industry’s largest companies, a simultaneous UK licensing and reimbursement decision for a heart medicine, and fresh evidence that the biotech listing window remains firmly open.
GSK reported second-quarter results on 28 July showing turnover of £8.4 billion, up 5 per cent at constant exchange rates, and core operating profit of £2.8 billion, up 7 per cent, both ahead of analyst consensus. Alongside the figures the company launched Accelerate Growth, a three-year restructuring programme targeting £1.9 billion of annual savings by 2029 for expected total costs of £2.4 billion, of which £2.1 billion is cash. Savings will be reinvested primarily in research and development, with a portion used to support operating margin through the loss of exclusivity for dolutegravir between 2028 and 2030. GSK said the savings will be enabled by technology and artificial intelligence, and generated by streamlining support services and process redesign including procurement, the reallocation of resources to specialty medicines from established products, and further simplification of the supply chain and site network. The company has not quantified any effect on headcount. GSK now expects to start more than 20 Phase 3 trials in 2026, double its previous target, having identified seven assets for acceleration across 18 indications in oncology, respiratory, hepatology and vaccines. The company also confirmed a £400 million UK investment over three years, centred on a new flagship research and development centre at the Cambridge Biomedical Campus. Total operating profit fell 75 per cent at constant rates to £481 million, driven largely by a £1.3 billion impairment following the discontinuation of camlipixant after Phase 3 results in chronic cough. Chief Executive Luke Miels said the programme is designed to simplify the organisation and reallocate capital and resources. Full-year guidance was reaffirmed, with turnover growth expected in the upper half of its 3 to 5 per cent range and core earnings per share growth in the lower half of its 7 to 9 per cent range. The 2031 sales outlook of more than £40 billion was maintained, and a second-quarter dividend of 17p was declared.
AstraZeneca published half-year results on 27 July reporting total revenue of $30.7 billion for the first six months of 2026, up 6 per cent at constant exchange rates and 9 per cent at actual rates, with core operating profit and core earnings per share both up 11 per cent at constant exchange rates. Double-digit growth in oncology and rare disease offset the loss of US exclusivity for Farxiga and continued pricing pressure from China’s volume-based procurement programme. The board raised the interim dividend by 3 cents to $1.06 per share, and the company recorded 30 approvals in major regions since its fourth-quarter 2025 results. Chief Executive Pascal Soriot pointed to six positive Phase 3 programmes and eight first approvals in major markets during the half, including US clearance of Baxfendy, which the company describes as its first-in-class hypertension medicine, while acknowledging disappointment at the CARDIO-TTRansform outcome. Full-year guidance was reconfirmed at constant exchange rates, with total revenue expected to grow by a mid-to-high single-digit percentage and core earnings per share by a low double-digit percentage. AstraZeneca restated its ambition of $80 billion in total revenue by 2030, citing more than 20 high-value readouts due over the next 18 months.
The Medicines and Healthcare products Regulatory Agency granted a UK marketing authorisation on 30 July for Cytokinetics’ MYQORZO (aficamten) in symptomatic obstructive hypertrophic cardiomyopathy in eligible adults of New York Heart Association class II to III, with NICE publishing final guidance recommending the medicine in England and Wales on the same day. NICE estimates that around 6,600 people in England could be eligible, and said it published its guidance two weeks faster than under its standard process as a result of closer working with the MHRA. The two organisations said it was the first time NICE had published final guidance on the same day a medicine received its UK marketing authorisation. Aficamten is a reversible cardiac myosin inhibitor and becomes the second medicine of its class available in the UK, after mavacamten. NICE recommended it through a cost comparison process, conditional on the company supplying it under the agreed commercial arrangement, and limited use to an add-on to individually optimised standard care including beta blockers, non-dihydropyridine calcium channel blockers or disopyramide, or alone where those treatments are contraindicated. NHS England is required to make the treatment available within 30 days of publication. Julian Beach, MHRA Executive Director of Healthcare Quality and Access, said the authorisation alongside NICE’s final guidance marks an important milestone for patients and for the UK’s medicines regulatory system, while Helen Knight, Director of Medicines Evaluation at NICE, said the decision demonstrates the value of aligning licensing and value assessment decisions.
Bristol Myers Squibb reported second-quarter results on 30 July with revenues of $13.0 billion, up 6 per cent, and raised its full-year outlook. Growth Portfolio revenues, covering newer medicines including Opdivo Qvantig, Reblozyl, Camzyos, Breyanzi and Opdualag, rose 15 per cent to $7.6 billion, offsetting a decline in legacy products to $5.4 billion as generic competition continued. GAAP earnings were $1.62 per share and non-GAAP earnings $2.04 per share, both comfortably ahead of consensus estimates. The company lifted full-year revenue guidance to a range of approximately $49.0 billion to $50.0 billion, from a previous range of approximately $46.0 billion to $47.5 billion, and increased its non-GAAP earnings per share range to $6.75 to $7.00. Board Chair and Chief Executive Christopher Boerner said the Growth Portfolio represents an expanding share of the overall business and that consistent execution and continued momentum had allowed the company to raise its outlook.
Apnimed priced an upsized initial public offering on 30 July, selling 12 million shares at $16.00 each for expected gross proceeds of $192 million, above its original 10 million share plan and at the top of its $14 to $16 marketed range. The Cambridge, Massachusetts company began trading on the Nasdaq Global Select Market under the ticker APMD on 31 July, with underwriters holding a 30-day option over a further 1.8 million shares. Proceeds will support preparations for the potential launch of AD109, an oral fixed-dose therapy for obstructive sleep apnoea that has completed two Phase 3 trials and carries an FDA target action date of 28 February 2027. Three further clinical-stage biotechs set terms in the same week, positioning the trio to net more than $500 million between them. Braveheart Bio, developing the cardiac myosin inhibitor BHB-1893 licensed from Jiangsu Hengrui, is offering about 18.7 million shares at $15 to $17 for roughly $274.5 million net at the midpoint. Attovia Therapeutics, whose lead interleukin-31 candidate ATTO-1310 has completed Phase 1 dosing, is offering 12.5 million shares in the same range for about $182.4 million net at the midpoint. Vogenx is pursuing the smallest of the three, offering 6.25 million shares at $11 to $13 to fund the SGLT1 inhibitor mizagliflozin.
That’s your life science news digest for 3 August 2026, back next Monday with the latest from pharma, biotech and healthcare at www.lifesciencedaily.news. Catch up on the 27 July news roundup.
